Related Experiment Video
Updated: Jul 10, 2026
11:15
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Novel therapies for malignant gliomas
Robert Cavaliere1, Patrick Y Wen, David Schiff
1Division of Neuro-Oncology, Ohio State University, 463 Means Hall, 1654 Upham Drive, Columbus, OH 43210, USA. robert.cavaliere@osumc.edu
Neurologic Clinics
|October 30, 2007
Summary
Cytotoxic therapies offer modest benefits for glioblastoma (GBM). Identifying treatment-sensitive GBM subsets and understanding glioma stem cell biology are crucial for developing effective, tailored therapies.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Molecular Therapeutics
Background:
- Cytotoxic therapies have shown limited efficacy in improving glioblastoma (GBM) patient outcomes.
- Evidence suggests that specific subsets of high-grade gliomas exhibit sensitivity to current treatments.
- Identifying these sensitive subgroups is essential for optimizing treatment strategies and avoiding toxicity from ineffective therapies.
Purpose of the Study:
- To highlight the modest impact of cytotoxic therapies on glioblastoma outcomes.
- To emphasize the existence of treatment-sensitive glioma subsets.
- To underscore the importance of molecular understanding for future glioblastoma therapeutics.
Main Methods:
- Review of current cytotoxic therapy outcomes in glioblastoma.
- Analysis of molecular characteristics differentiating treatment-sensitive and resistant gliomas.
- Exploration of the role of glioma stem cells in therapeutic response.
Main Results:
- Cytotoxic therapies have yielded modest improvements in glioblastoma treatment.
- Distinct molecular profiles correlate with varying responses to therapy.
- Glioma stem cells represent a key area for understanding therapeutic resistance and sensitivity.
Conclusions:
- Future glioblastoma treatment advancements depend on a deeper understanding of molecular biology and stem cell characteristics.
- Personalized therapeutic approaches targeting specific tumor molecular profiles are essential.
- Continued research is vital for identifying novel biomarkers and developing effective, targeted therapies for glioblastoma.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...